Prostate Cancer

Prostate cancer is the most common cancer diagnosed among American men, accounting for nearly 200,000 new cancer cases in the United States each year.

Prostate cancer tends to occur most commonly in men over the age of 50, with a mean age at diagnosis of 66.  The incidence of prostate cancer increases with age; the lifetime risk for the average American man is about one-in-seven.  Well-established risk factors include older age, family history (esp. multiple first-degree male relatives diagnosed with prostate cancer at an early age), and race (African Americans and Caribbean men of African ancestry are at greater risk).  Other potential risk factors thought to be associated prostate cancer include a Western diet high in saturated fat and obesity.

The overwhelming majority of prostate cancers are adenocarcinomas, which arises from the glandular (acinar) component of the prostate.  Other rare and atypical types of prostate cancer include ductal carcinoma, mucinous carcinoma, signet-ring cell carcinoma, small cell carcinoma, clear cell adenocarcinoma and giant cell carcinoma. These rare and atypical variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.

The face of prostate cancer has changed significantly over the past decades.  Largely due to the widespread use of prostate specific antigen (PSA), most prostate cancers are now diagnosed at an earlier, more curable stage.  Although prostate cancer deaths have decreased in recent years, PSA screening continues to be controversial with concerns of over-screening, over-detection and over-treatment of indolent tumors.  Recently the American Urologic Association updated their recommendations on prostate cancer screening:

  • The American Urological Association firmly believes in the value of prostate cancer screening through shared decision-making with patients
  • Prostate cancer screening should include both a serum prostate specific antigen (PSA) test AND a digital prostate examination
  • Screening should be offered for men of average risk between the ages of 55-69 and individualized thereafter based upon a patient’s health and life expectancy
  • Earlier screening, starting at the age of 40, should be strongly considered for men with a positive family history or African-American race
  • Screening interval can be ever 1-2 years and individualized based on risk factors

Local Prostate Cancer

Approximately 90% of prostate cancers are diagnosed at a localized stage (cancer confined to prostate without evidence of spread).  Localized cancers are most commonly detected through an elevation in PSA without causing symptoms.  Less commonly, prostate cancer may be detected by an abnormal digital rectal exam (DRE) or due to urinary symptoms, such as hematuria (blood in the urine) or problems with urination (difficulty or discomfort with urination).  Not all local prostate cancers are the same.  Some are indolent and will not cause problems while others are clinically significant and require treatment.  Even among clinically significant cancers, there are differences that further separate cancers by risk (for example, low, intermediate and high risk prostate cancer).  Factors that determine the risk and clinical significance of prostate cancer include PSA, Gleason grade and disease stage.  There are several effective treatment options for men with clinically significant local prostate cancer, including surgery, external radiation therapy and interstitial brachytherapy.  Treatment recommendations are usually made based on a number of factors, including disease characteristics, risk category, candidacy for a particular treatment, and patient preference.  In some cases (low- and intermediate-risk prostate cancer, for example), a single treatment may be adequate for disease control.  For others, particularly in high-risk prostate cancer, a combination of treatments may be required.  For low-risk prostate cancer and among older men, active-surveillance (observation) is another management option.  Although effective in cancer control, most prostate cancer treatments carry some risk of impacting urinary, sexual and bowel health.  Newer treatment methods, however, continue to be developed to minimize the risks of these side effects (for example, nerve-sparing radical prostatectomy).  Following treatment, approximately 15% to 25% of patients with early-stage (localized) prostate cancer experience a biochemical (PSA) recurrence, indicating possible need for additional therapy.  However, the overall 5-year survival for patients with localized prostate cancer is close to 100%.

Top of Page


Advanced Prostate Cancer

Approximately 10% of prostate cancers are diagnosed at an advanced stage characterized by involvement of surrounding structures, spread to lymph nodes or metastasis to more distant sites.  Advanced prostate cancer more commonly causes some symptoms, such as hematuria, urinary obstruction or bone pain.  Treatment options for patients with metastatic prostate cancer are more limited, although in some settings, surgery or radiation therapy may still be indicated.  More commonly, androgen deprivation therapy (ADT), also known as hormone therapy, is used to control metastatic disease and slow the growth of more advanced prostate cancers.  Chemotherapy may also be used to manage patients with metastatic prostate cancer, although it is not a mainstay of management.  Common sites of metastatic spread include the bone, liver and lungs.  The overall 5-year survival for regionally advanced and metastatic prostate cancer is approximately 32%.

Top of Page


Our Surgeons 


Michael Blute_MCM_8491

Michael L. Blute, Jr., MD

Assistant Professor

 

 


Paul Crispen, M.D.

Paul L. Crispen, MD

Associate Professor
UF Health Cancer Center Scientific Review and Monitoring Committee Chair

 


Brandon Otto, MDBrandon J. Otto, MD

Assistant Professor

 


Li-Ming Su_MCM_5433_edit

Li-Ming Su, MD

David A. Cofrin Professor and Chairman

 


Top of Page


Signs & Symptoms

For most men, prostate cancer does not cause symptoms but is detected because of an elevation in prostate specific antigen (PSA).  However, symptoms of the lower urinary tract, such as hematuria (blood in the urine), frequency (need to urinate frequently) and dysuria (discomfort or pain with urination) may be signs of prostate problems, including prostate cancer.  Other uncommon symptoms of prostate cancer can include urinary retention, weight loss, abdominal pain, bone pain, or fracture.

Lower Urinary Tract Symptoms (Prostatism)

  • Frequency
  • Urgency
  • Hematuria (visible or microscopic)
  • Dysuria
  • Urinary retention

Pain Symptoms

  • Back pain
  • Pelvic pain
  • Bone pain

Constitutional Symptoms

  • Weight loss

Diagnosis

  • Physical examination
  • PSA blood test
  • Prostate biopsy
  • Abdominal and pelvic CT scan
  • Bone scan (if indicated)

After taking a detailed medical history and performing a physical examination, including a digital rectal examination, a PSA blood test will be performed.  If the PSA level is elevated, a prostate biopsy will be recommended.  The biopsy is an outpatient procedure (you go home the same day) that is performed with local anesthesia.  Several samples of tissue are obtained from the prostate.  These samples are what tell us if you have prostate cancer.  If the biopsy is positive, other tests may be performed based on your PSA level, cancer grade and findings on exam.  Most commonly, a CT scan of the abdomen and pelvis will be obtained for clinical staging.  In high-risk cases, a bone scan may be recommended to determine if there has been spread to the bones.

Top of Page


Staging for Prostate Cancer

Clinical staging is performed with Physical Examination and Abdominal and Pelvic CT scan.  In cases of advanced or high-risk disease, additional testing such as Bone Scan may be necessary.

The prognosis of prostate cancer is directly linked to the stage of disease.  Staging is a process that demonstrates how far the cancer has spread.  Both treatment options and prognosis (or outlook) for prostate cancer depend significantly on the stage of disease.

TNM System stands for Tumor, Lymph Nodes, and Metastasis.

TNM SYSTEM

Status

T0

No evidence of primary prostate tumor

T1

Clinically inapparent tumor not palpable or visable by imaging

T1a

Tumor incidental histologic finding in <5% of removed tissue

T1b

Tumor incidental histologic finding in >5% of removed tissue

T1c

Tumor identified by needle biopsy because of elevated PSA

T2

Tumor confined with the prostate

T2a

Tumor involves one-half of one lobe or less

T2b

Tumor involves > one-half of one lobe but not both lobes

T2c

Tumor involves both lobes

T3

Tumor extends through the prostate capsule

T3a

Extracapsular extension (unilateral or bilateral)

T3b

Tumor invades seminal vesicle(s)

T4

Tumor fixed or invades adjacent pelvic structures

N0

No regional lymph node metastasis

N1

Metastasis in regional lymph node or nodes

M0

No distant metastasis

M1

Distant metastasis

M1a

Metastasis to non-regional lymph node(s)

M1b

Metastasis to bone(s)

M1c

Metastasis to other site(s)

Top of Page


Treatment

Most prostate cancers are localized and can be treated with surgery, external radiation therapy or interstitial brachytherapy.  In low-risk disease, observation or active surveillance may also be an option.  Focal therapy using ablative technology is less common and is currently under investigation.  Treatments for localized prostate cancer include:

  • 3D-conformal radiation therapy
  • Active Surveillance (observation)
  • Focal therapy
  • Intensity-modulated radiation therapy
  • Interstitial brachytherapy
  • Radical perineal prostatectomy
  • Radical retropubic prostatectomy
  • Robotic-assisted laparoscopic prostatectomy
  • Salvage Therapy

3D conformal and Intensity-Modulated Radiation Therapy

Radiation therapy is an effective treatment for prostate cancer and can be used to manage low and high-risk cases.  Currently, two types of external radiation therapy are used.  3D-conformal RT targets the prostate with the aid of imaging guiding to more accurately deliver radiation dose to the prostate with less radiation therapy exposure to surrounding tissues.  Intensity-modulated RT uses more advanced technology to reduce dose to the areas of the bladder, rectum and bowel and boost dose to the prostate.  For both modalities, a total radiation dose of 76 Gy should be administered and some studies have shown that higher doses are more effective.  Radiation therapy is typically given in daily fractions over the course of 10 weeks.  In intermediate- and high-risk prostate cancer, RT should be administered with ADT to maximize the treatment effect.

Active surveillance (observation)

is used in some cases of low-risk disease, as well as among older patients for whom active treatment with surgery or radiation therapy may not be possible or necessary.  Active surveillance is most often used because some prostate cancers may never become life threatening.  PSA and DRE are typically checked periodically, and current active surveillance protocols recommend repeat biopsies to ensure that disease does not progress.

Interstitial prostate brachytherpay involves placement of small radioactive pellets, or “seeds” into the prostate.  In general, this treatment can be used for small to normal sized prostates and for Gleason grade 6 or less tumors.  In settings of higher risk disease (PSA>10 ng/mL or Gleason grade ³ 7) where there is concern for extraprostatic extension, external radiation therapy should be used in conjunction with interstitial bracytherapy to ensure adequate cancer control.  In some cases, hormone therapy may be used before brachytherapy to help reduce the size of the prostate.

Focal therapy

Ablative therapies such as cryoablation, radiofrequency ablation and high-frequency ultrasonic ablation are currently being studied as a way to limit treatment to the focal location of the cancer instead of treating the entire prostate with the hopes that focal therapy will be associated with fewer side effects than other non-focal treatments.  Selection of appropriate, low-risk patients is essential because less therapy may not be adequate to control higher-volume or high-risk prostate cancer.  Other concerns regarding focal therapy include targeting the tumor within the prostate accurately, identifying other areas of cancer within the prostate and offering more effective management compared to active surveillance.

Radical perineal prostatectomy

consists of removal of the prostate through an incision in the perineum (the area between the scrotum and anus), and was the first surgical approach used to treat prostate cancer.  Today, perineal prostatectomy is relatively uncommon, but it is still used in certain cases, such as in obese patients in which access to the prostate from pelvis would be difficult.  In intermediate and high-risk cases in which lymph node dissections are indicated, a separate lymph node dissection may be indicated to complete staging. Because it is an uncommon surgery, the surgeon should be familiar in this surgical approach.

Radical retropubic prostatectomy (RRP)

consists of removal of the prostate gland and surrounding lymph nodes through an 8 cm open incision above the pubic bone.  Radical retropubic prostatectomy is the most common open surgical approach to treating prostate cancer, and can be used to treat a range of prostate cancer, including low, intermediate and high-risk localized prostate cancer, as well as radiation refractory prostate cancer (termed salvage prostatectomy).  Most patients spend 1-2 nights in the hospital and are sent home with a urinary (Foley) catheter, which stays in for a week following surgery to encourage healing of the urethra.  Depending on the stage and risk of the disease, radical retropubic prostatectomy can be performed with nerve-sparing.  Nerve-sparing prostatectomy provides the best chance of return of erections following surgery in men with good erectile function prior to treatment, and is typically used in low and intermediate-risk disease.  In setting of high-risk disease, however, nerve-sparing may not be indicated as it may limit cancer control (removal of all cancer tissue).  Like other types of surgical therapy, outcomes following radical retropubic prostatectomy (cancer control, urinary continence, erectile function and complications) tend to be better, on average, when preformed by high-volume and fellowship-trained surgeons.

Robotic-assisted laparoscopic prostatectomy

is one of the most common types of surgical treatments for prostate cancer, and its use in the management of localized prostate cancer has increased rapidly in recent years.  The robotic approach takes advantage of the benefits of laparoscopy as well as small surgical working elements that replicate the movement of the human hand.  In general, RALP is associated with less blood loss, a lower chance of requiring a blood transfusion, decreased pain post-operatively, and shorter convalescence.  As with RRP, lymph nodes are removed with the prostate for pathologic staging.  Patients tend to spend 1-2 nights in the hospital and are sent home with a urinary (Foley) catheter that stays in place for 7 to 10 days.  As with open surgery, this procedure should be performed by a surgeon familiar with the robot and who is trained in performing radical prostatectomy.  In general, high-volume (those surgeons who perform many procedures) and fellowship surgeons tend to have better outcomes than low-volume and non-fellowship-trained surgeons.

Salvage therapy

In cases of prostate cancer recurrence following primary treatment, a secondary local therapy can lead to salvage and cure.  Depending on which type of treatment was first used, salvage surgery, radiation therapy or cyro-abalation may be used to control recurrent disease.

Top of Page